Targeting MDSC differentiation using ATRA: a phase I/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma

RP Tobin, DT Cogswell, VM Cates, DM Davis… - Clinical Cancer …, 2023 - AACR
Purpose: A phase Ib/II clinical trial was conducted to evaluate the safety and efficacy of the
combination of all-trans retinoic acid (ATRA) with pembrolizumab in patients with stage IV …

[HTML][HTML] MAIT cells: partners or enemies in cancer immunotherapy?

DT Cogswell, L Gapin, HM Tobin, MD McCarter… - Cancers, 2021 - mdpi.com
Simple Summary Unconventional T cells have recently come under intense scrutiny
because of their innate-like effector functions and unique antigen specificity, suggesting their …

Circulating CD8+ mucosal‐associated invariant T cells correlate with improved treatment responses and overall survival in anti‐PD‐1‐treated melanoma patients

…, KL Couts, CM Amato, DT Cogswell… - Clinical & …, 2022 - Wiley Online Library
Objectives While much of the research concerning factors associated with responses to
immune checkpoint inhibitors (ICIs) has focussed on the contributions of conventional peptide‐…

Developing preliminary blood metabolomics-based biomarkers of insufficient sleep in humans

CM Depner, DT Cogswell, PJ Bisesi, RR Markwald… - Sleep, 2020 - academic.oup.com
Study Objective Identify small molecule biomarkers of insufficient sleep using untargeted
plasma metabolomics in humans undergoing experimental insufficient sleep. Methods We …

Melanoma metastases to the adrenal gland are highly resistant to immune checkpoint inhibitors

…, RJ Van Gulick, CM Amato, DT Cogswell… - Journal of the National …, 2021 - jnccn.org
Background: Adrenal gland metastases (AGMs) are common in advanced-stage melanoma,
occurring in up to 50% of patients. The introduction of immune checkpoint inhibitors (ICIs) …

Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma.

M McCarter, RP Tobin, DT Cogswell, VM Vorwald… - 2021 - ascopubs.org
9536 Background: Myeloid-derived suppressor cells (MDSCs) are potent suppressors of
antitumor immunity and are commonly associated with poor outcomes in melanoma patients …

Targeting the RIG-I-like receptor signaling pathway to improve the efficacy of immunotherapy in mucosal and uveal melanoma.

ML MacBeth, RJ Van Gulick, RP Tobin, DT Cogswell… - 2021 - ascopubs.org
e21593 Background: Patients with cutaneous (CM) or acral (AM) melanoma have high
response rates to immune checkpoint blockade (ICB) therapies including anti-CTLA4, anti-PD1, …

Circulating CD8+ MAIT cells correlate with improved outcomes in anti-PD1 treated melanoma patients

…, KL Couts, CM Amato, DT Cogswell, M Fujita, T Davis… - medRxiv, 2020 - medrxiv.org
While much of the research concerning factors associated with responses to immunotherapies
focuses on the contributions of conventional peptide-specific T cells, the role of …

Identification of a preliminary plasma metabolome-based biomarker for circadian phase in humans

D Cogswell, P Bisesi, RR Markwald… - Journal of biological …, 2021 - journals.sagepub.com
Measuring individual circadian phase is important to diagnose and treat circadian rhythm
sleep-wake disorders and circadian misalignment, inform chronotherapy, and advance …

[PDF][PDF] Targeting MDSCs using ATRA: a phase I/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma

R Tobin, D Cogswell, V Vorwald, D Davis, J Borgers… - pdfs.semanticscholar.org
… By inhibiting the functions of CD8+ T cells, MDSCs eliminate a highly effective mechanism
of antitumor immunity, as CD8+ T cells express the targets of ICIs and are important effectors …